Advanced search
Publication Cover
Drug Development and Industrial Pharmacy Volume 33, 2007 - Issue 9
Submit an article Journal homepage
110
Views
4
CrossRef citations to date
0
Altmetric
Research Article

Studies on Bi-Layer Osmotic Pump Tablets of Water-Insoluble Allopurinol with Large Dose: In Vitro and In Vivo

Shu-fang Nie School of Pharmacy, Shenyang Pharmaceutical University, Shenyang, P.R. China
,
Wei Li School of Pharmacy, Shenyang Pharmaceutical University, Shenyang, P.R. China
,
Lin Luan School of Pharmacy, Shenyang Pharmaceutical University, Shenyang, P.R. China
,
Weisan Pan School of Pharmacy, Shenyang Pharmaceutical University, Shenyang, P.R. China
&
Xun Wang Department of Pharmaceutics, Peking University, Beijing, P.R. China
Pages 1024-1029 | Published online: 26 Sep 2008

REFERENCES

  • Barthel W., Hüller G, Haustein K. O., et al. Bioequivalence of Allopurinol-containing tablet preparations. Int. J. Clin. Pharmacol. Ther. 1999; 37(3)148–152
  • Chen M. L., André J. J. The role of metabolites in bioequivalency assessment. I. Linear pharmacokinetics without first-pass effect. Pharm. Res. 1991; 8(1)25–32
  • Chen C. M., Lee D. Y., Xie J. Controlled release formulation for water insoluble drugs in which a passageway is formed in situ [P]. US Patent: 5736159, 1998-04-07, 1998
  • FDA. 1995. Guidance for Industry: SUPAC-IR: Immediate-Release Solid Oral Dosage Forms: Scale-Up and Post-Approval Changes: Chemistry, Manufacturing and Controls, In Vitro Dissolution Testing, and In Vivo Bioequivalence Documentation (I).
  • Goldenberg M. M. An extended-release formulation of oxybutynin chloride for the treatment of overactive urinary bladder. Clin Ther. 1999; 21(4)634–642
  • Gupta S. K., Shah J. C., Guinta D., et al. Multiple-dose pharmacokinetics and pharmacodynamics of OROS and immediate-release amitriptyline hydrocholoride formulations. J. Clin. Pharmacol. 1998; 38(1)60–67
  • Hou H. M., Zhu J. P. The preparation and in vitro release of OROS(indometacin). Chin. J. Hospital Pharm. 1982; 2(5)265–266
  • Keith S. Advances in psychotropic formulations. Prog. Neuro-Psychopharmacol. Biol. Psychiatry. 2006; 30(6)996–1008
  • Kuczynski A. L., Ayer A. D., Wong P. S. L., et al. Oral hypoglycemic glipizide granulation [P]. US:5024843, 1991-06-18, 1991
  • Liu L., Ku J., Khang G., et al. Nifedipine controlled delivery by sandwished osmotic tablet system. J. Control. Release. 2000; 68(2)145–156
  • Modi N. B., Lindemulder B., Gupta S. K. Single- and multi-dose pharmacokinetics of an oral once-a-day osmotic controlled-release OROS (methylphenidate HCl) formulation. J. Clin. Pharmacol. 2000; 40(4)379–388
  • Okimoto K., Miyake M., Ohnishi N. Design and evaluation of an osmotic pump tablet (OPT) for prednisolone, a poorly water soluble drug using (SBE)7m-β-CD. Pharm. Res. 1998; 15(10)1562–1568
  • Okimoto K., Rajewski R. A., Stella V. J. Factors affecting membrane-controlled drug release for an osmotic pump tablet (OPT) utilizing (SBE)7m-β-CD as both a solubilizing and osmotic agent. J. Control. Release. 1999; 60(2–3)311–319
  • Okimoto K., Rajewski R. A., Stella V. J. Release of testosterone from an osmotic pump tablets (OPT) utilizing (SBE)7m-β-cyclodextrin as both a solubilizing and osmotic pump agent. J. Control. Release. 1999; 58(1)29–38
  • Okimoto K., Rajewski R. A., Stella V. J. Design and evaluation of an osmotic pump tablet (OPT) for chlorpromazine using (SBE)7m-β-CD. Pharm. Res. 1999; 16(4)549–554
  • Swanson D. R., Barclay B. L., Wong P. S. L., et al. Nifedipine gastrointestinal therapeutic system. Am. J. Med. 1987; 83: 3
  • Thombre A. G., Appel L. E., Chidlaw M. B., et al. Osmotic drug delivery using swellable- core technology. J. Control. Release. 2004; 75: 75–89
  • Verma R. K., Krishna D. M., Garg S. Formulation aspects in the development of osmotically controlled oral drug delivery systems. J. Control. Release 2000b; 79: 7–27
  • Verma R. K., Mishra B., Garg S. Osmotically controlled oral drug delivery. Drug Dev. Ind. Pharm. 2000a; 26(7)695–708
  • Walter-Sack I., de Vries J. X., Ernst B., et al. Uric acid lowering effect of oxipurinol sodium in hyperuricemic patients. Therapeutic equivalence to allopurinol. J. Rheumatol. 1996; 23: 498–501
  • Walter-Sack I., de Vries J. X., Kreiner C., et al. Disposition and uric acid lowering effect of oxipurinol: Comparison of different oxipurinol formulations and allopurinol in healthy individuals. Eur. J. Clin. Pharmacol. 1995; 49: 215–220

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.